Medannex completes final tranche of £11m Series B investment, led by Morningside Venture Capital

17 August 2020

Medannex has completed the final tranche of its Series B investment of £11 million, led by Boston-based global Life Sciences investor Morningside Ventures. 

The first tranche was received in July 2019, and the completion of this investment is testimony to the progress Medannex has made since then. This includes generating exciting non-clinical data on the company’s anticancer agent MDX-124, presented at a Nature Reviews Cancer conference and the AACR annual meeting.

Medannex is now focused on preparations for a First-in-Human study in 2021.